{
    "Trade/Device Name(s)": [
        "ADVIA Centaur BR"
    ],
    "Submitter Information": "Siemens Healthcare Diagnostics Inc.",
    "510(k) Number": "K193489",
    "Predicate Device Reference 510(k) Number(s)": [
        "K982680"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MOI"
    ],
    "Summary Letter Date": "December 16, 2019",
    "Summary Letter Received Date": "December 17, 2019",
    "Submission Date": "December 13, 2019",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-Associated Antigen Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "CA 27.29"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (EDTA)"
    ],
    "Specimen Container(s)": [
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "ADVIA Centaur",
        "ADVIA Centaur XP",
        "ADVIA Centaur XPT"
    ],
    "Method(s)/Technology(ies)": [
        "Competitive immunoassay",
        "Direct chemiluminescent technology"
    ],
    "Methodologies": [
        "Immunological testing",
        "Chemiluminescent immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent Kit",
        "Calibrator",
        "Pretreatment Reagent",
        "Diluent",
        "Master Curve Material"
    ],
    "Document Summary": "FDA 510(k) summary for ADVIA Centaur BR assay for quantitative measurement of CA 27.29 in serum and plasma (EDTA) for monitoring breast cancer.",
    "Indications for Use Summary": "Intended as an aid in monitoring patients previously treated for Stage II or III breast cancer and managing patients with metastatic breast cancer, using serial CA 27.29 measurements in serum and plasma (EDTA), in conjunction with other clinical methods.",
    "fda_folder": "Immunology"
}